TY - JOUR
AU1 - Colantonio, Lisandro
AU2 - Deng, Luqin
AU3 - Chen, Ligong
AU4 - Farkouh, Michael
AU5 - Monda, Keri
AU6 - Harrison, David
AU7 - Maya, Juan
AU8 - Kilgore, Meredith
AU9 - Muntner, Paul
AU1 - Rosenson, Robert
AB - Purpose Compare medical expenditures among adults with statin-associated adverse effects (SAAE) and high statin adherence (HSA) following myocardial infarction (MI). Methods We analyzed expenditures in 2016 US dollars among Medicare beneficiaries with SAAE (n = 1741) and HSA (n = 55,567) who were ≥ 66 years of age and initiated moderate/high-intensity statins following an MI in 2007–2013. SAAE were identified through a claims-based algorithm, which included down-titrating statins and initiating ezetimibe, switching to ezetimibe monotherapy, having a rhabdomyolysis or antihyperlipidemic adverse event followed by statin down-titration or discontinuation, or switching between ≥ 3 statin types within 365 days following MI. HSAwas defined by having a statin available to take for ≥ 80% of the days in the 365 days following MI. Results Expenditures among beneficiaries with SAAE and HSA were $40,776 (95% CI $38,329–$43,223) and $26,728 ($26,482–$26,974), respectively, in the 365 days following MI, and $34,238 ($31,396–$37,080) and $29,053 ($28,605–$29,500), respectively, for every year after the first 365 days. Multivariable-adjusted ratios comparing expenditures among beneficiaries with SAAE versus HSA in the first 365 days and after the first 365 days following MI were 1.51 (95% CI 1.43–1.59) and 1.23 (1.12–1.34), respectively. Inpatient and outpatient expenditures were higher among beneficiaries 
TI - Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction
JF - Cardiovascular Drugs and Therapy
DO - 10.1007/s10557-018-6840-8
DA - 2018-11-16
UR - https://www.deepdyve.com/lp/springer-journals/medical-expenditures-among-medicare-beneficiaries-with-statin-BvqPpNgnpF
SP - 601
EP - 610
VL - 32
IS - 6
DP - DeepDyve
ER -